OpenAI releases new voice models for more natural live conversations

Did we make the wrong bet on ‘Big A.I.’?

As enterprises struggle to manage their AI strategies, the US AI regulatory environment is sending a wide range of contradictory signals. OpenAI’s Wednesday announcement that it will now release GPT-5.6 Sol, along with Terra and Luna, on Thursday highlights the confusion. Initially, the US government said that it was asking OpenAI to limit access to its top models, including the three releasing Thursday, to a short list of companies. OpenAI seemingly agreed and held back their general availability. But on Wednesday, OpenAI reversed its position, with a statement on X saying simply: “GPT-5.6 Sol, along with Terra and Luna, will launch publicly this Thursday. We’re expanding preview access globally now.” No details were released about the extent of the expansion. Then the White House issued a statement, a copy of which it emailed to InfoWorld, saying that the US government “did not give OpenAI a ‘green light,’ approval or clearance to release its models. No such permission is required or

The post Boom Times For Autoimmune Disease Therapies appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more. To get it in your inbox, subscribe here. AbbVie’s Skyrizi is on track to become the world’s second-highest selling drug, according to pharma consultants Evaluate. The Associated Press AbbVie’s Skyrizi, an injectable drug for autoimmune diseases that include psoriasis and Crohn’s disease, is expected to surpass $33 billion in revenue in 2032, making it the world’s second-biggest selling drug, according to a recent report from pharma data and consulting firm Evaluate. That puts it smack between Eli Lilly’s GLP-1 blockbusters, Mounjaro (for diabetes) and Zepbound (for weight loss). “Only autoimmune disease drugs come close to rivaling Lilly’s anti-obesity blockbusters given their potential to treat dozens of conditions driven by s

As enterprises struggle to manage their AI strategies, the US AI regulatory environment is sending a wide range of contradictory signals. OpenAI’s Wednesday announcement that it will now release GPT-5.6 Sol, along with Terra and Luna, on Thursday highlights the confusion. Initially, the US government said that it was asking OpenAI to limit access to its top models, including the three releasing Thursday, to a short list of companies. OpenAI seemingly agreed and held back their general availability. But on Wednesday, OpenAI reversed its position, with a statement on X saying simply: “GPT-5.6 Sol, along with Terra and Luna, will launch publicly this Thursday. We’re expanding preview access globally now.” No details were released about the extent of the expansion. Then the White House issued a statement, a copy of which it emailed to InfoWorld, saying that the US government “did not give OpenAI a ‘green light,’ approval or clearance to release its models. No such permission is required or

GPT-Live's real-time voice capabilities could redefine AI interactions, influencing market dynamics and competitive AI advancements. The post OpenAI unveils GPT-Live, enhancing ChatGPT with real-time voice capabilities appeared first on Crypto Briefing.

GPT-Live-1's full-duplex capability enhances real-time interaction, potentially transforming human-AI communication dynamics and applications. The post OpenAI launches GPT-Live-1, a full-duplex voice model that talks and listens at the same time appeared first on Crypto Briefing.

Microsoft plans to focus more on in-house AI models in an effort to reduce its costs for generative AI (genAI), Bloomberg reports. The company has begun using its own MAI models to handle some user AI requests in Word and Excel rather than relying solely on models from OpenAI and Anthropic. The company still uses third-party models, but has invested increasingly in its own AI solutions over the past year. At the Build developer conference in June, Microsoft unveiled seven new MAI models, including an AI code assistant and an image-generation model. As the costs of advanced genAI models have risen, several tech companies — including Amazon, Meta, and Accenture — have reportedly been trying to find ways to reduce their expenses.

OpenAI's IPO and BofA's involvement could reshape AI investment dynamics, impacting both centralized and decentralized AI market strategies. The post BofA extends $520M loan to OpenAI ahead of IPO appeared first on Crypto Briefing.